Vivos Therapeutics (VVOS) 2025 Annual Meeting Results (Form 8-K)

Vivos Therapeutics held its Annual Meeting on November 4, 2025. Stockholders voted on three key proposals:

• Board Elections: All six Director Nominees (including R. Kirk Huntsman) were elected to one-year terms expiring in 2026. Director votes showed strong support, though significant broker non-votes were present (~2 million shares).
• Equity Plan: Stockholders approved an amendment to the 2024 Omnibus Equity Incentive Plan.
• Auditors: Ratification passed for Baker Tilly US, LLP to replace Moss Adam